Drugs not directly targeting VEGF are also a possibility, such as the Ref-1 inhibitor APX3330, effective as a systemic agent for choroidal neovascularization in mice and currently entering a Phase II trial as an oral tablet for diabetic macular edema (NCT04692688)16. Here, VEGFA is linked to diabetic macular edema.